NIPT市场萎缩、核心团队出走、美国设备禁令,这家 基因测序 独角兽的上市之路布满荆棘。出生率跌破0.7%的警报声中,安诺优达的产前检测试剂盒正面临前所未有的需求塌方。招股书显示,中国出生率从2018年的1.1%骤降至2024年的0.7%,且预计将长期维持在0.6%的历史低位。这对高度依赖NIPT(无创产前检测)产品的安诺优达构成致命威胁——临床测序解决方案贡献了63.7%的收入,其中NIPT...
Source LinkNIPT市场萎缩、核心团队出走、美国设备禁令,这家 基因测序 独角兽的上市之路布满荆棘。出生率跌破0.7%的警报声中,安诺优达的产前检测试剂盒正面临前所未有的需求塌方。招股书显示,中国出生率从2018年的1.1%骤降至2024年的0.7%,且预计将长期维持在0.6%的历史低位。这对高度依赖NIPT(无创产前检测)产品的安诺优达构成致命威胁——临床测序解决方案贡献了63.7%的收入,其中NIPT...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.